Phosphofructokinase 2/fructose 2,6-bisphosphatase 3 performs crucial roles in glycolysis and lactate production in tumor cells [33], and the combination inhibitor PFK-158 targets PFKFB3 with cytotoxic T lymphocyte antigen 4 and enhances therapeutic efficacy in a melanoma model [34]. Here, PFKFB3 is linked to melanoma.